Literature DB >> 14675348

The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.

H-S Moon1, W I Park, E-A Choi, H-W Chung, S-C Kim.   

Abstract

The present study aimed to confirm the hypothesis that the expression and phosphorylation status of the E-cadherin/catenin adhesion complex is related to cervical carcinogenesis and cervical cancer invasion, and to investigate the expression and the tyrosine phosphorylation of focal adhesion kinase (FAK) and its relation with E-cadherin/catenin adhesion complex. The expression of E-cadherin, alpha- and beta-catenin, and FAK were studied by a western blot analysis with 26 cervical carcinomas, nine normal cervices, and five carcinomas in situ of cervix. The tyrosine phosphorylation of alpha- and beta-catenin and FAK were examined by an immunoprecipitation. The expressions of alpha- and beta-catenin and E-cadherin were reduced in cervical carcinoma, and the tyrosine phosphorylation of alpha- and beta-catenin in cervical carcinoma was higher than in normal cervix and carcinoma in situ of cervix. Tyrosine phosphorylation of FAK was elevated in cervical carcinoma although the expression of FAK was not significantly different. Moreover, alpha- and beta-catenin were coimmunoprecipitated with FAK. We conclude that the loss of E-cadherin/catenin proteins and the tyrosine phosphorylation of E-cadherin/catenin are involved in cervical carcinogenesis and cancer invasion. Tyrosine phosphorylation of focal adhesion kinase is also related to the cervical cancer invasion. The E-cadherin/catenin complex and FAK may be related functionally and structurally.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675348     DOI: 10.1046/j.1525-1438.2003.13396.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  17 in total

Review 1.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.

Authors:  Duangmani Thanapprapasr; Wei Hu; Anil K Sood; Robert L Coleman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Expression of focal adhesion kinase in small-cell lung carcinoma.

Authors:  Sebahat Ocak; Heidi Chen; Clay Callison; Adriana L Gonzalez; Pierre P Massion
Journal:  Cancer       Date:  2011-07-28       Impact factor: 6.860

Review 3.  Focal adhesion kinase as a cancer therapy target.

Authors:  Vita M Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

4.  Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism.

Authors:  Parimal Sheth; Ankur Seth; Katherine J Atkinson; Tarun Gheyi; Gautam Kale; Francesco Giorgianni; Dominic M Desiderio; Chunying Li; Anjaparavanda Naren; Radhakrishna Rao
Journal:  Biochem J       Date:  2007-03-01       Impact factor: 3.857

5.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

6.  OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization.

Authors:  Fazal H Tabassam; David Y Graham; Yoshio Yamaoka
Journal:  Cell Microbiol       Date:  2007-12-06       Impact factor: 3.715

7.  Focal adhesion kinase regulates cell-cell contact formation in epithelial cells via modulation of Rho.

Authors:  Martin P Playford; Kavita Vadali; Xinming Cai; Keith Burridge; Michael D Schaller
Journal:  Exp Cell Res       Date:  2008-08-23       Impact factor: 3.905

Review 8.  Targeting FAK in human cancer: from finding to first clinical trials.

Authors:  Vita M Golubovskaya
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01

9.  Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study.

Authors:  Sang Jin Kim; Jin Woo Park; Ji Sung Yoon; Ji O Mok; Yeo Joo Kim; Hyeong Kyu Park; Chul Hee Kim; Dong Won Byun; Yong Jin Lee; So Young Jin; Kyo Il Suh; Myung Hi Yoo
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

10.  Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line.

Authors:  Yuh-Cheng Yang; Tsung-Chuan Ho; Show-Li Chen; Huei-Yi Lai; Ju-Yun Wu; Yeou-Ping Tsao
Journal:  BMC Cancer       Date:  2007-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.